Funding profile · Pharma regulatory and labeling AI
Entvin
A software company with one disclosed funding event: $500,000 from Y Combinator, reported in March 2025, about two and a half years after its 2022 founding. No SEC Form D has been filed under the Entvin name.
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2022 | Y Combinator, Summer 2022 | Not disclosed | Y Combinator | YC data |
| Mar 2025 | First reported funding round | $500,000 (reported as Rs 5 crore) | Y Combinator | Press reports |
What the filings show
No Form D, and no other filing of any kind, appears under “Entvin” in a September 25, 2026 SEC EDGAR company search, despite the company’s reported $500,000 raise a year and a half earlier. That gap is not unusual on its own: Y Combinator’s standard investment is typically structured as a SAFE, and a SAFE that stays below certain thresholds or is not followed by a priced equity round does not always trigger a Form D. It does mean the $500,000 figure rests entirely on the company’s own statements to reporters, repeated across roughly a dozen outlets in the days after March 28, 2025, and not on any document filed with a regulator.
The one filing this research did find is a corporate registration, not a securities filing. Entvin Labs Private Limited, incorporated in Bengaluru on August 19, 2022 and registered with India’s Ministry of Corporate Affairs under CIN U72900KA2022FTC165078, is classified as a subsidiary of a company incorporated outside India, meaning the US entity, Entvin, Inc. Its authorized share capital is Rs 10,00,000 and its paid-up capital is Rs 1,00,000, about $1,200 at current exchange rates. That paid-up figure describes the Indian subsidiary’s own share capital, not the group’s total funding, and should not be read as a measure of the company’s overall resources.
Reading the record
- One round, many retellings.The same $500,000 figure, sourced to a single company announcement, ran in at least seven outlets between March 28 and April 3, 2025: Business Standard, Entrackr, Express Pharma, Healthcare Radius, Indian Startup News, StartupTalky and VCCircle. None appears to have reported independently verified terms; all describe it as Entvin’s first round.
- The India entity predates the round by two and a half years.Entvin Labs Private Limited was incorporated in August 2022, the same year Y Combinator accepted the company, but the first disclosed outside check did not land until March 2025. That gap suggests the founders were either self-funding or running on undisclosed early capital for an extended stretch, which is common but not confirmed here.
- No later Form D has appeared.If Entvin raised additional capital after the Y Combinator check, whether through a priced round or another SAFE, it has not shown up in EDGAR under the company’s name as of this writing.
- The India subsidiary’s paid-up capital is a rounding error next to the reported raise.Rs 1,00,000 is roughly a quarter of one percent of $500,000. It confirms the subsidiary exists and is lightly capitalized on paper, not that meaningful operating funds route through it.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Product | Two named products, Labeling AI and Ads Promo AI, for FDA and EMA label tracking and promotional material review. | Company-stated |
| Customers | Website states the platform is “Trusted by R&D and pharma professionals from world’s leading organisations” and carries testimonials identified only by job title. No customer named. | Company-stated |
| Certifications | Company and press quotes claim SOC 2, ISO 27001, HIPAA and GDPR compliance. No certificate or auditor found. | Company-stated |
| Team | 5 employees per Y Combinator; 2 to 10 per LinkedIn. | YC and LinkedIn data |
| Founder roster | Y Combinator lists two Active Founders, Sanskar Jain and Hemant Phalak. March and April 2025 press coverage names a third, CTO Rishabh Arya, who is not a director of the India subsidiary. | Differs from press coverage |
What to watch
- Any Form D filed under Entvin, which would put an SEC-sourced number on the company’s capital for the first time.
- Whether Rishabh Arya remains with the company, given his absence from Y Combinator’s current founder listing and from the India subsidiary’s director records.
- A named customer or a disclosed revenue figure.
The Entvin story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordEntvin Labs Private Limited, CIN U72900KA2022FTC165078, MCA registry data
- Not foundSEC EDGAR company search, “Entvin”
- YC dataEntvin company page
- CompanyEntvin (YC S22) company page
- CompanyEntvin homepage
- IndependentEntvin AI raises Rs 5 crore in first funding round from Y Combinator
- IndependentEntvin AI raises $500K from Y Combinator
- IndependentEntvin AI raises $500K in Y Combinator funding to streamline FDA drug approval process
- IndependentPharma Breakthrough: Entvin AI Lands $500K for FDA Boost
- IndependentIIT Bombay graduates-founded startup Entvin AI raises $500,000 from Y Combinator
- IndependentIIT Bombay Graduates’ Startup Entvin AI Secures USD 500,000 from Y Combinator
- IndependentEvenflow, Wendor, Entvin AI, The Bear House, InnerGize raise funding
Compiled from SEC and India Ministry of Corporate Affairs public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; no such notice was found for Entvin. Healthcare Venture Capital Fund holds no position in Entvin. This page is not an offer to sell or a recommendation to buy any security.